LivaNova PLC (LIVN)
Automate Your Wheel Strategy on LIVN
With Tiblio's Option Bot, you can configure your own wheel strategy including LIVN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol LIVN
- Rev/Share 23.4349
- Book/Share 19.0055
- PB 2.2714
- Debt/Equity 0.6554
- CurrentRatio 1.5793
- ROIC 0.1013
- MktCap 2353874469.0
- FreeCF/Share 2.674
- PFCF 16.1752
- PE -10.5758
- Debt/Assets 0.2649
- DivYield 0
- ROE -0.1811
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | LIVN | Wolfe Research | Peer Perform | Outperform | -- | $60 | May 20, 2025 |
| Downgrade | LIVN | Wolfe Research | Outperform | Peer Perform | -- | -- | Feb. 26, 2025 |
| Initiation | LIVN | Goldman | -- | Buy | -- | $65 | Oct. 4, 2024 |
| Upgrade | LIVN | Robert W. Baird | Neutral | Outperform | $55 | $66 | Sept. 17, 2024 |
News
LivaNova (LIVN) Q1 Earnings and Revenues Surpass Estimates
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Positive
LivaNova (LIVN) came out with quarterly earnings of $0.88 per share, beating the Zacks Consensus Estimate of $0.75 per share. This compares to earnings of $0.73 per share a year ago.
Read More
LivaNova Reports First-Quarter 2025 Results; Updates 2025 Guidance
Published: May 07, 2025 by: Business Wire
Sentiment: Neutral
LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the first quarter ended March 31, 2025 and updated full-year 2025 guidance. Financial Summary and Highlights(1) First-quarter revenue of $316.9 million increased 7.4% on a reported basis, 8.9% on a constant-currency basis, and 10.4% on an organic basis as compared to the prior-year period First-quarter U.S. GAAP diluted loss per share of $6.01, impacted by recording SNIA.
Read More
LivaNova Announces 12-month Data from OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea, Demonstrating Strong Response and Durability of Therapy
Published: May 07, 2025 by: Business Wire
Sentiment: Neutral
LONDON--(BUSINESS WIRE)-- #livn--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced 12-month, top-line data from its OSPREY randomized controlled trial (RCT), evaluating outcomes with the aura6000™ System for the treatment of moderate to severe obstructive sleep apnea (OSA). At 12 months of therapy, the treatment arm responder rate was 65% with responders defined as those who realized at least a 50% improvement from the baseline apnea-hypopnea index (AHI) and an A.
Read More
About LivaNova PLC (LIVN)
- IPO Date 2015-10-19
- Website https://www.livanova.com
- Industry Medical - Devices
- CEO Mr. Vladimir A. Makatsaria
- Employees 2900